FDA Announcement Expands Options for Cervical Cancer Screening

ASCCP releases statement in response to FDA Announcement.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This

Frederick, MD (PRWEB) April 26, 2014

The FDA announced on Thursday approval of a Human papillomavirus (HPV) test for primary cervical cancer screening among women ages 25 and older. As a result, physicians and clinicians are turning to the American Society for Colposcopy and Cervical Pathology (ASCCP), the interdisciplinary society for lower genital tract disorders for up-to-date direction.

ASCCP Chief Medical Officer, Dr. Herschel Lawson, comments, “We’re energized by the attention to this important women’s health issue and the opportunity to increase available cervical cancer screening tools for the medical community. While existing guidelines for use of cervical cytology alone and cytology/HPV cotesting are not likely to change in the near future, we look forward to providing guidance for integrating primary HPV testing into our collection of recommended screening protocols to facilitate individual patient needs for appropriate cervical cancer screening and indicated follow up."

ASCCP will continue working with many organizations and provider groups impacted by the announcement and is collaborating with the Society for Gynecologic Oncology (SGO) to develop an interim guidance document for further clarification on use of the newly approved test. In the meantime, providers are encouraged to continue using currently published screening and management guidelines.

About ASCCP
Now in its 50th year, the ASCCP continues to hold Biennial Scientific Meetings to support its primary educational mission: To improve clinician competence and performance and patient outcomes through educational activities focused on the study, prevention, diagnosis, and management of lower genital tract disorders. The ASCCP was founded in 1964 and is a 501 (c)(3) organization.